10-Q: GT Biopharma Reports Q2 2024 Results, Advances Clinical Programs

GT Biopharma reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and financial position.

Summary

• GT Biopharma is a clinical-stage biopharmaceutical company focused on developing immuno-oncology products.
• The company's proprietary TriKE and Dual Targeting TriKE platforms are designed to enhance the cancer-killing abilities of a patient's natural killer cells.
• For the six months ended June 30, 2024, GT Biopharma reported a net loss of approximately $6.0 million and used $7.7 million in operating activities.
• As of June 30, 2024, the company had cash and cash equivalents and short-term investments totaling $9.2 million, working capital of $5.8 million, and stockholders' equity of $5.5 million.
• The company received FDA clearance for its Investigational New Drug (IND) application for GTB-3650 in late June 2024 and anticipates starting patient enrollment in the second half of 2024.
• GT Biopharma is also advancing GTB-5550 through preclinical studies and plans to submit an IND application in the first half of 2025.

Sentiment

Score: 4

Explanation: The document highlights positive clinical progress and FDA clearance, but the company's financial situation and going concern issues temper the overall sentiment. The increased net loss and reliance on future financing are significant concerns.

Positives

• FDA clearance for the GTB-3650 IND application is a significant milestone.
• The company is advancing a promising next-generation TriKE (GTB-3650) with enhanced potency.
• The company has a pipeline of TriKE product candidates targeting both hematological malignancies and solid tumors.
• The company has secured $3.2 million in gross proceeds from a common stock offering in May 2024.
• The company has a strong research collaboration with the University of Minnesota.

Negatives

• The company has a history of operating losses and expects these to continue.
• The company has not generated any revenue from product sales.
• The company's auditors have raised doubts about its ability to continue as a going concern.
• The company's net loss increased to $5.976 million for the six months ended June 30, 2024, compared to $2.219 million for the same period in 2023.
• The company's cash used in operating activities was $7.7 million for the six months ended June 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing.
• Failure to secure additional financing could force the company to delay, reduce, or eliminate some or all of its discretionary spending.
• The company is involved in several legal proceedings, including disputes with former executives.
• The company is dependent on third-party manufacturers and research partners.
• Clinical trials may not be successful, and product candidates may not receive regulatory approval.

Future Outlook

The company anticipates starting patient enrollment for GTB-3650 in the second half of 2024 and plans to submit an IND application for GTB-5550 in the first half of 2025. The company expects its direct clinical and preclinical expenses to increase in the second half of 2024.

Management Comments

• The company is focused on the development and commercialization of novel immuno-oncology products.
• The company believes its TriKEs may have the ability to be used as both monotherapy and in combination with other standard-of-care therapies.
• The company is putting processes in place to be able to produce investigational new drug (IND) ready moieties in a timely manner after a specific TriKE conceptual design.

Industry Context

GT Biopharma is operating in the competitive immuno-oncology space, focusing on novel therapies that harness the power of natural killer cells. The company's TriKE platform represents a unique approach to cancer treatment, differentiating it from traditional antibody-based therapies and CAR-T cell therapies. The company is targeting both hematological malignancies and solid tumors, which are areas of significant unmet medical need.

Comparison to Industry Standards

• GT Biopharma's approach of using TriKE technology to engage natural killer cells is a novel approach compared to traditional antibody-based therapies like those developed by companies such as Genentech (Roche) or CAR-T cell therapies from companies like Gilead or Novartis.
• The company's focus on both hematological malignancies and solid tumors is similar to the broad approach taken by companies like Bristol Myers Squibb and Merck, but with a different technology platform.
• The company's financial position, with $9.2 million in cash and cash equivalents, is relatively modest compared to larger pharmaceutical companies, but is typical for a clinical-stage biotech company.
• The company's research and development expenses of $2.561 million for the six months ended June 30, 2024, are lower than those of larger companies, reflecting its stage of development and focus on preclinical and early clinical trials.
• The company's net loss of $6.0 million for the six months ended June 30, 2024, is typical for a clinical-stage biotech company that is not yet generating revenue from product sales.

Management Changes

Legal Proceedings

• The company filed an AAA Arbitration Demand against its former Chief Financial Officer, Manu Ohri, for breach of fiduciary duties and breach of contract.
• The company is involved in a lawsuit filed by former interim CEO, Dr. Gregory Berk, alleging discrimination and retaliation for whistleblowing activity.
• The company is involved in a legal dispute with TWF Global, LLC regarding convertible promissory notes.
• The company received a final arbitration award in its favor against former CFO Michael Handelman, including legal fees, costs, and the return of disputed shares.

Related Party Transactions

• The company has significant accounts payable and accrued expenses to Cytovance Biologics, Inc., a related party.
• The company issued 127,597 shares of common stock to Cytovance to settle accounts payable valued at approximately $810,000 during the six months ended June 30, 2024.
• The company has a scientific research agreement and a sponsored research agreement with the Regents of the University of Minnesota.

Stakeholder Impact

• Shareholders face the risk of dilution from potential future capital raises.
• Employees may be impacted by potential cost-cutting measures if the company fails to secure additional financing.
• Customers (potential patients) may benefit from the development of new cancer therapies.
• Suppliers and creditors may be impacted by the company's financial instability.
• The company's ability to continue operations is dependent on securing additional financing, which could impact all stakeholders.

Next Steps

• The company plans to start patient enrollment for GTB-3650 in the second half of 2024.
• The company plans to submit an IND application for GTB-5550 in the first half of 2025.
• The company will continue to advance its preclinical programs and seek additional financing.

Key Dates

Keywords

TriKE, immuno-oncology, natural killer cells, GTB-3650, GTB-5550, FDA, clinical trials, biopharmaceutical, cancer therapy, AML, MDS, B7-H3, CD33